J2H-1802

**J2H-1802** is an orally administered, preclinical small-molecule hybrid anti-inflammatory candidate developed by J2H Biotech. Published murine studies describe it as a newly synthesized hybrid compound based on structural elements attributed to mycophenolate mofetil and 5-aminosalicylic acid. In imiquimod-induced psoriasis-like mice, J2H-1802 reduced clinical and histologic inflammation, splenomegaly, serum tumor necrosis factor-alpha, and skin expression of interleukin-1 beta, interleukin-6, interleukin-17, and tumor necrosis factor-alpha. In dextran sulfate sodium-induced colitis mice, it reduced disease activity and inflammatory mediators and was associated with suppression of nuclear factor kappa-light-chain-enhancer of activated B cells signaling and cyclooxygenase-2 expression. It has not been reported in human clinical trials.

Other names

J2H 1802J-2H 1802J 2H 1802